2. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004; 291:2616–2622.
3. Mayor S. Cardiovascular disease threatens developing countries. BMJ. 2004; 328:1032.
4. Statistics Korea. Annual report on the cause of death statistics 2010. Daejeon: Statistics Korea;2011.
5. Finch CA, Lenfant C. Oxygen transport in man. N Engl J Med. 1972; 286:407–415.
6. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, Levey AS. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) Study. J Am Coll Cardiol. 2002; 40:27–33.
7. Kunnas T, Solakivi T, Huuskonen K, Kalela A, Renko J, Nikkari ST. Hematocrit and the risk of coronary heart disease mortality in the TAMRISK Study, a 28-year follow-up. Prev Med. 2009; 49:45–47.
8. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, Mendelssohn D, Tobe S, Singer J, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis. 2001; 38:1398–1407.
9. Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost. 2007; 33:321–329.
10. Tong PC, Kong AP, So WY, Ng MH, Yang X, Ng MC, Ma RC, Ho CS, Lam CW, Chow CC, et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in chinese patients with type 2 diabetes. Diabetes Care. 2006; 29:2439–2444.
11. Carter C, McGee D, Reed D, Yano K, Stemmermann G. Hematocrit and the risk of coronary heart disease: the Honolulu Heart Program. Am Heart J. 1983; 105:674–679.
12. Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, Park SW, Yun YD, Baek SJ, Mok Y, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study. Diabetes Care. 2013; 36:328–335.
13. Campbell MJ, Elwood PC, Mackean J, Waters WE. Mortality, haemoglobin level and haematocrit in women. J Chronic Dis. 1985; 38:881–889.
14. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease: the Framingham study: a 34-year follow-up. Am Heart J. 1994; 127:674–682.
15. Brown DW, Giles WH, Croft JB. Hematocrit and the risk of coronary heart disease mortality. Am Heart J. 2001; 142:657–663.
16. Zakai NA, Katz R, Hirsch C, Shlipak MG, Chaves PH, Newman AB, Cushman M. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med. 2005; 165:2214–2220.
17. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. High blood hemoglobin concentration as risk factor of major atherosclerotic cardiovascular events in 114,159 healthy men and women in the apolipoprotein mortality risk study (AMORIS). Ann Med. 2012; 44:476–486.
18. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke. 2009; 40:3422–3427.
19. Jee SH, Park JW, Lee SY, Nam BH, Ryu HG, Kim SY, Kim YN, Lee JK, Choi SM, Yun JE. Stroke risk prediction model: a risk profile from the Korean study. Atherosclerosis. 2008; 197:318–325.
20. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurol Clin. 2008; 26:871–895.
21. Smith S, Julius S, Jamerson K, Amerena J, Schork N. Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan. J Hypertens. 1994; 12:455–462.
22. Burch GE, DePasquale NP. Hematocrit, viscosity and coronary blood flow. Dis Chest. 1965; 48:225–232.
23. Lowe GD, Forbes CD. Platelet aggregation, haematocrit, and fibrinogen. Lancet. 1985; 1:395–396.
24. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992; 86:803–811.
25. Bellotto F, Cati A. Anemia and myocardial ischemia: relationships and interferences. Recenti Prog Med. 2006; 97:153–164.
26. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl. 2002; (80):35–38.
27. Coppola L, Guastafierro S, Sagristani M, Coppola A, Nasuti A, Ruggiero L, De Biase M, Tirelli A, Gombos G. Decreased hemoglobin levels are associated with higher plasma level of fibrinogen, irrespective of age. Am J Med Sci. 2007; 333:154–160.
28. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352:1011–1023.
29. Llauradó G, Ceperuelo-Mallafré V, Vilardell C, Simó R, Freixenet N, Vendrell J, González-Clemente JM. Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: a potential role of low-grade inflammation. Diabetes Care. 2012; 35:1083–1089.
30. Mattson MP. Hormesis and disease resistance: activation of cellular stress response pathways. Hum Exp Toxicol. 2008; 27:155–162.
31. Terplan M. Menstruation and cardiovascular vulnerability. Arch Intern Med. 2005; 165:120.
32. Park JK, Kim KS, Kim CB, Lee TY, Lee KS, Lee DH, Lee S, Jee SH, Suh I, Koh KW, et al. The accuracy of ICD codes for cerebrovascular diseases in medical insurance claims. Korean J Prev Med. 2000; 33:76–82.
33. Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM. Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med. 2009; 169:515–523.